Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The investigators performed a randomized, double-blind controlled, prospective study method
on observation of Traditional Chinese Medicine combined with targeted therapy to prolong the
efficacy of long-term survival of advanced pulmonary Adenocarcinoma patients.The
investigators plan to involve 404 cases for observation in 3 years (202 cases for each
group), expecting that integrated TCM combined with targeted therapy has a better efficacy on
prolonging progression-free survival time, overall survival, improving QOL of patients than
that of targeted therapy.
Details
Lead Sponsor:
Shanghai University of Traditional Chinese Medicine